Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Aug;54(2):140-6.
doi: 10.1046/j.1365-2125.2002.01620.x.

An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria

Affiliations

An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria

Angela Matthews et al. Br J Clin Pharmacol. 2002 Aug.

Abstract

Aims: To investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of betaine in the treatment of classical homocystinuria due to cystathionine beta-synthase (CbetaS) deficiency with a view to optimizing the dosage regimen.

Methods: Betaine was given as a single oral dose of 100 mg kg(-1) to six patients (age range 6-17 years) who normally received betaine but whose treatment had been suspended for 1 week prior to the study. Plasma betaine and total homocysteine concentrations were measured by high performance liquid chromatography (h.p.l.c.) at frequent intervals over 24 h. The best-fit PK model was determined using the PK-PD program Win-Nonlin and the concentration-time-effect data analysed by an indirect PD model. Using the PK and PD parameters, simulations were carried out with the aim of optimizing betaine dosage.

Results: Betaine PK was described by both mono- and bi-exponential disposition functions with first order absorption and a lag time. The correlation coefficient between betaine oral clearance and body weight was 0.6. Mean betaine clearance was higher in males than in females (P=0.03). PK-PD simulation indicated minimal benefit from exceeding a twice-daily dosing schedule and a 150 mg kg(-1) day(-1) dosage for betaine.

Conclusions: PK-PD modelling allows recommendations for optimal dosage of betaine in the treatment of homocystinuria, that have the potential for improved patient compliance and both therapeutic and pharmacoeconomic benefit.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The metabolic cycle of methionine and the possible enzyme defects in homocystinuria (cross signs: bold cross indicating patients in this study). The mechanism of action of administered betaine is indicated. R(t) is the concentration of homocysteine at a given time, C(t) is the concentration of betaine at a given time, kin and kout are rate constants for the production and loss of homocysteine, respectively, S(t) is a stimulation function for the betaine induced increase in homocysteine elimination.
Figure 2
Figure 2
Representative best fit model (line) to plasma betaine concentrations(•) in subject 1 and subject 2. Biexponential and monoexponential disposition with first-order absorption were assumed for subjects 1 and 2, respectively.
Figure 3
Figure 3
Representative change in plasma total homocysteine as a function of plasma betaine concentration in subject 2 showing counter-clockwise hysteresis.
Figure 4
Figure 4
A representative model fit (solid line) to homocysteine-time data (▴) following administration of 100 mg kg−1 day−1 of betaine to subject 1.
Figure 5
Figure 5
Simulated effects of administering 100 mg kg−1 day−1 of betaine as a twice daily dose on plasma betaine concentration (a) and the predicted effects on plasma total homocysteine concentration (b). Simulation for subject 2.
Figure 6
Figure 6
Simulated effects of increasing dose frequency on the relative decrease in plasma total homocysteine in six patients receiving a fixed dose of 100 mg kg−1 day−1 of betaine (▴ = subject 1, □ = subject 2, ▪ = subject 3, ○ = subject 4, • = subject 5, ▵ = subject 6).
Figure 7
Figure 7
Simulated effects of increasing the betaine dose on the overall reduction in Plasma total homocysteine concentration in 6 patients on a fixed twice-daily dosing schedule (▴ = subject 1, □ = subject 2, ▪ = subject 3, ○ = subject 4, • = subject 5, ▵ = subject 6).

References

    1. Mudd SH, Levy HL, Skovby F. Disorders of transsulphation. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease. 7. New York: McGraw-Hill; 1995. pp. 1279–1327.
    1. Fenton WA, Rosenberg LE. Inherited disorders of cobolamin transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease. 7. New York: McGraw-Hill; 1995. pp. 3129–3149.
    1. Rosenblatt DS. Inherited disorders of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic Basis of Inherited Disease. 7. New York: McGraw-Hill; 1995. pp. 3111–3128.
    1. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 1985;37:1–31. - PMC - PubMed
    1. Wilcken DEL, Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis. 1997;20:295–300. - PubMed